Optimizing the Management of Acute Diarrhoeal Disease

PHASE3CompletedINTERVENTIONAL
Enrollment

276

Participants

Timeline

Start Date

June 30, 2016

Primary Completion Date

January 31, 2019

Study Completion Date

February 28, 2019

Conditions
Acute Gastroenteritis
Interventions
OTHER

Rapid diagnostics

Participants will have enteric specimens obtained using a flocked rectal swab, which will be transported in 2 mL Cary Blair medium. These will be tested using the BioMerieux BioFire FilmArray GI panel.

BIOLOGICAL

Probiotic

The probiotic given will be Lactobacillus reuteri DSM 17938, 5x10e8 cfu/mL x 60 days, suspended in vegetable oil.

OTHER

Placebo

The placebo will be the vegetable oil vehicle and look identical to the probiotic.

Trial Locations (4)

Unknown

Princess Marina Hospital, Gaborone

Deborah Retief Hospital, Mochudi

Scottish Livingstone Hospital, Molepolole

Bamalete Lutheran Hospital, Ramotswa

Sponsors

Collaborators (2)

All Listed Sponsors
collaborator

Grand Challenges Canada

OTHER

collaborator

BioMérieux

INDUSTRY

collaborator

BioGaia AB

INDUSTRY

collaborator

Copan Italia S.A.

UNKNOWN

collaborator

Botswana-UPenn Partnership

OTHER

collaborator

University of British Columbia

OTHER

lead

Hamilton Health Sciences Corporation

OTHER

NCT02803827 - Optimizing the Management of Acute Diarrhoeal Disease | Biotech Hunter | Biotech Hunter